The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

Oral and poster presentations of its DZD8586 study results in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) are selected by ASCO Scientific Program Committee. In ...

“Right now, only 20% of patients with EGFR-positive NSCLC survive beyond five years,” explained Joshua Bauml, vice president, ...

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

In addition, Dizal will present its 4 th generation EGFR TKI clinical data in non-small cell lung cancer (NSCLC) during the conference. DZD8586 is a first-in-class, non-covalent, LYN/BTK dual ...

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...